How Ketamine Rewires Receptors to Beat Depression TL;DR: Using PET imaging to directly visualize AMPA receptors in the living human brain, researchers discovered that ketamine’s rapid antidepressant effect works by reshuffling these receptors across specific brain regions in patients with treatment-resistant depression — and where they go predicts who will respond to the drug. Nearly …
How Scientists Turned a Brief Ketamine High into a Two-Month Antidepressant Effect TL;DR: Blocking DUSP6 protein alongside ketamine extends antidepressant effects from 2 weeks to 4+ weeks in mice, potentially offering single-dose treatment instead of repeated infusions. Ketamine works like almost nothing else in psychiatry. A single infusion can lift severe depression within hours, even …
Opioid System Activation is Required for Ketamine’s Antidepressant Effects Ketamine is fast—a single subanesthetic infusion reduces severe depression symptoms within hours, not weeks. But the mechanism remains incompletely understood. For nearly two decades, research assumed glutamate flooding the brain explained everything: ketamine blocks NMDA receptors on inhibitory neurons, releasing the brakes on glutamate release, which …
Ketamine significantly reduces suicidal ideation in depressed patients, with rapid effects observed within the first day of treatment. Highlights: Rapid Reduction: Ketamine shows a significant reduction in suicidal ideation within the first day of treatment (RR = 10.02, 95% CI = 4.24 to 23.68). Sustained Improvement: Repeated ketamine treatments result in a greater reduction of …
A study examined the effects of ketamine on sleep arousal metrics in individuals with treatment-resistant depression (TRD) vs. healthy volunteers, finding that ketamine increases certain sleep-related brain activities but does not significantly mediate its antidepressant effects through these sleep changes. Highlights: Individuals with TRD had lower total sleep time and shorter REM latency compared to …
The European Medicines Agency (EMA) has updated its guidance on clinical trials for new depression treatments, with the goals of harmonizing standards across the EU and facilitating development of improved therapies. Key Facts: Depression is a highly disabling condition affecting many worldwide, which has been exacerbated by the COVID-19 pandemic Up to 2/3 of patients …
Depression affects over 300 million people globally. Current treatments have limited efficacy for many patients. Exciting new research highlights the potential of allopregnanolone agonists like brexanolone and zuranolone as more targeted, rapid-acting antidepressants. Key Facts: Allopregnanolone is a neurosteroid that regulates mood and is decreased in depression. Its agonists boost allopregnanolone activity. Brexanolone is the …
Major depressive disorder affects over 17 million American adults each year. For up to 30% of these patients, standard antidepressant medications fail to provide adequate symptom relief – a condition known as treatment-resistant depression (TRD). Now, new research suggests amphetamine-based stimulants like Adderall may be an effective augmentation strategy for TRD when other therapies have …
Vagus nerve stimulation (VNS) is an emerging form of brain stimulation showing promise for treating depression. Though still considered experimental, VNS has a long history dating back over 100 years. Recent advances are unlocking its potential as a new tool for mood disorders. Key Facts: VNS stimulates the vagus nerve, which connects to emotion regulation …
Deep brain stimulation (DBS), a surgical procedure that implants electrodes in the brain to deliver electrical stimulation, may offer hope for people with severe depression that has not responded to multiple treatments. However, larger and more rigorous studies are still needed to confirm its benefits and long-term safety. Key Facts: DBS targets areas of the …
